Demand for next-generation GLP-1 drugs is fueling a boom in peptide research, prompting companies like Sai Life Sciences to expand capabilities amid a hot market for obesity and diabetes treatments. “The GLP-1 agonists have exploded the peptide field,” said Maneesh Pingle, Ph.D., executive vice president and head of discovery services at Sai Life Sciences, in… The post Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center appeared first on Drug...| Drug Discovery and Development
In what will soon be commonplace in drug research, scientists have used an artificial-intelligence algorithmic program to identify a compound, currently used in antimalarial treatment, that can effectively reverse the bone deterioration of osteoporosis.| New Atlas
Here are eight nanotechnology companies that are widening the scope in medicine, that you should know about.| Labiotech.eu